Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH)
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if orlistat (Xenical) therapy in overweight
patients with NASH leads to enhanced weight loss over time, with subsequent improvement in
the underlying necroinflammatory and fibrotic changes that are typical of NASH.